Lionco Pharmaceutical Group (603669.SH) subsidiary's product has been selected for inter-provincial alliance procurement of injected huperzine A.

Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., participated in the bidding for the inter-provincial alliance centralized volume purchasing of 34 types of drugs led by Henan Province. According to the Inter-provincial Alliance Procurement Office for 34 types of drugs announcement released on August 11, 2026, on the Henan Province Medical Centralized Procurement Platform, the subsidiarys product, injectable huperzine A (brand name: Ruilisu), was selected for this procurement. It is reported that this medication is suitable for benign memory disorders, enhancing patients' abilities in pointing memory, associative learning, image recall, recognition of meaningless patterns, and portrait memory. It also has a positive effect on memory disorders caused by dementia and organic brain lesions. Additionally, this product is used for the treatment of myasthenia gravis. Being selected is beneficial for increasing the national market share of injectable huperzine A (brand name: Ruilisu) in the fields of cognitive impairment and myasthenia gravis treatment, thereby enhancing the companys brand influence.